|
US5516931A
(en)
|
1982-02-01 |
1996-05-14 |
Northeastern University |
Release tag compounds producing ketone signal groups
|
|
US4709016A
(en)
|
1982-02-01 |
1987-11-24 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
|
US4650750A
(en)
|
1982-02-01 |
1987-03-17 |
Giese Roger W |
Method of chemical analysis employing molecular release tag compounds
|
|
US5650270A
(en)
|
1982-02-01 |
1997-07-22 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
|
US5217866A
(en)
|
1985-03-15 |
1993-06-08 |
Anti-Gene Development Group |
Polynucleotide assay reagent and method
|
|
US5360811A
(en)
|
1990-03-13 |
1994-11-01 |
Hoechst-Roussel Pharmaceuticals Incorporated |
1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
|
|
JP3545461B2
(ja)
|
1993-09-10 |
2004-07-21 |
エーザイ株式会社 |
二環式ヘテロ環含有スルホンアミド誘導体
|
|
WO1996007655A1
(en)
|
1994-09-06 |
1996-03-14 |
Banyu Pharmaceutical Co., Ltd. |
Novel carbapenem derivative
|
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
|
US6306663B1
(en)
|
1999-02-12 |
2001-10-23 |
Proteinex, Inc. |
Controlling protein levels in eucaryotic organisms
|
|
EP1382339B1
(en)
|
1999-12-10 |
2007-12-05 |
Pfizer Products Inc. |
Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
|
|
DE10002509A1
(de)
|
2000-01-21 |
2001-07-26 |
Gruenenthal Gmbh |
Substituierte Glutarimide
|
|
ES2243461T3
(es)
|
2000-02-28 |
2005-12-01 |
Sugen, Inc. |
Compuestos de 3-(pirolillactona) -2-indolinona como inhibidores quinasa.
|
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
|
US7041298B2
(en)
|
2000-09-08 |
2006-05-09 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US7208157B2
(en)
|
2000-09-08 |
2007-04-24 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
WO2002078617A2
(en)
*
|
2001-03-28 |
2002-10-10 |
University Of South Florida |
Materials and methods for treatment of cancer and identification of anti-cancer compounds
|
|
EP1389617B1
(en)
|
2001-04-27 |
2007-01-03 |
Zenyaku Kogyo Kabushiki Kaisha |
Heterocyclic compound and antitumor agent containing the same as active ingredient
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
WO2004019973A1
(en)
|
2002-08-14 |
2004-03-11 |
Atugen Ag |
Use of protein kinase n beta
|
|
KR20070087266A
(ko)
|
2003-04-03 |
2007-08-28 |
세마포르 파머슈티컬즈, 아이엔씨. |
피아이-3 키나아제 억제제 프로드러그
|
|
CN1832939B
(zh)
|
2003-05-30 |
2010-04-28 |
杰明X医药品加拿大公司 |
用于治疗癌症或病毒病的三杂环化合物、组合物和方法
|
|
US7173015B2
(en)
|
2003-07-03 |
2007-02-06 |
The Trustees Of The University Of Pennsylvania |
Inhibition of Syk kinase expression
|
|
PT1701941E
(pt)
|
2003-12-11 |
2012-08-03 |
Univ Texas |
Compostos para o tratamento de doenças proliferativas celulares
|
|
JP4398263B2
(ja)
|
2004-01-13 |
2010-01-13 |
富士通株式会社 |
経路設計方法
|
|
US7436318B2
(en)
|
2004-04-19 |
2008-10-14 |
Atg Designworks, Llc |
Self contained device for displaying electronic information
|
|
SI2612862T1
(sl)
|
2004-05-13 |
2017-04-26 |
Icos Corporation |
Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
|
|
US20060005147A1
(en)
|
2004-06-30 |
2006-01-05 |
Hammack Jason L |
Methods and systems for controlling the display of maps aboard an aircraft
|
|
US20070010428A1
(en)
|
2004-09-03 |
2007-01-11 |
Mcmurray John S |
Inhibitors of signal transduction and activator of transcription 3
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
DE602006010979D1
(de)
|
2005-01-19 |
2010-01-21 |
Rigel Pharmaceuticals Inc |
Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
|
CA2599393A1
(en)
|
2005-02-25 |
2006-08-31 |
The Regents Of The University Of Michigan |
Small molecule inhibitors of stat3 and the uses thereof
|
|
AU2006230099B2
(en)
|
2005-03-25 |
2012-04-19 |
Gitr, Inc. |
GITR binding molecules and uses therefor
|
|
EP1888550B1
(en)
|
2005-05-12 |
2014-06-25 |
AbbVie Bahamas Ltd. |
Apoptosis promoters
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
US7402325B2
(en)
|
2005-07-28 |
2008-07-22 |
Phoenix Biotechnology, Inc. |
Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
|
|
US20080139456A1
(en)
|
2005-09-30 |
2008-06-12 |
Burke Terrence R |
Macrocyclic Sh2 Domain Binding Inhibitors
|
|
BRPI0617162B8
(pt)
|
2005-10-07 |
2021-05-25 |
Exelixis Inc |
compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
|
|
NZ567266A
(en)
|
2005-10-13 |
2010-09-30 |
Orchid Res Lab Ltd |
Carbazole derivatives as pSTAT3/IL-6 inhibitors (carvedilol)
|
|
CN103626742B
(zh)
|
2005-11-01 |
2017-04-26 |
塔格根公司 |
激酶的联-芳基间-嘧啶抑制剂
|
|
EP2455382B1
(en)
|
2005-12-13 |
2016-10-26 |
Incyte Holdings Corporation |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
|
|
UA96283C2
(uk)
|
2005-12-23 |
2011-10-25 |
Зіланд Фарма А/С |
Модифіковані міметики лізину
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
MX2008013578A
(es)
|
2006-04-26 |
2009-03-23 |
Hoffmann La Roche |
Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
|
|
US7960434B2
(en)
|
2006-05-19 |
2011-06-14 |
University Of South Florida |
Small molecule inhibitors of STAT3 with anti-tumor activity
|
|
BRPI0622054B8
(pt)
|
2006-09-22 |
2021-05-25 |
Oxford Amherst Llc |
composto e composição farmacêutica
|
|
UA95978C2
(ru)
|
2006-10-02 |
2011-09-26 |
Оцука Фармас'Ютікел Ко., Лтд. |
Ингибитор активации stat3/5
|
|
WO2008067270A1
(en)
|
2006-11-27 |
2008-06-05 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Macrocyclic grb2 sh2 domain-binding inhibitors
|
|
HRP20151386T1
(hr)
|
2007-03-12 |
2016-02-26 |
Ym Biosciences Australia Pty Ltd |
Fenil aminopirimidinski spojevi i njihova primjena
|
|
WO2008118802A1
(en)
|
2007-03-23 |
2008-10-02 |
Regents Of The University Of Minnesota |
Therapeutic compounds
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
WO2008156644A2
(en)
|
2007-06-14 |
2008-12-24 |
Frank David A |
Stat modulators
|
|
ES2776406T3
(es)
|
2007-07-12 |
2020-07-30 |
Gitr Inc |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
|
WO2009032338A1
(en)
|
2007-09-09 |
2009-03-12 |
University Of Florida Research Foundation |
Apratoxin therapeutic agents: mechanism and methods of treatment
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
JP5583592B2
(ja)
|
2007-11-30 |
2014-09-03 |
ニューリンク ジェネティクス コーポレイション |
Ｉｄｏ阻害剤
|
|
FR2927330B1
(fr)
|
2008-02-07 |
2010-02-19 |
Sanofi Aventis |
Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
|
|
US8158616B2
(en)
|
2008-03-11 |
2012-04-17 |
Incyte Corporation |
Azetidine and cyclobutane derivatives as JAK inhibitors
|
|
JP2011518841A
(ja)
|
2008-04-24 |
2011-06-30 |
ニューリンク ジェネティクス， インコーポレイテッド |
Ｉｄｏ阻害剤
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
NZ590372A
(en)
|
2008-07-08 |
2012-09-28 |
Univ Texas |
Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
WO2010077589A2
(en)
|
2008-12-08 |
2010-07-08 |
The Regents Of The University Of Michigan Office Of Technology Transfer |
Stat3 inhibitors and therapeutic methods using the same
|
|
AU2009333580B2
(en)
|
2008-12-09 |
2016-07-07 |
Genentech, Inc. |
Anti-PD-L1 antibodies and their use to enhance T-cell function
|
|
US8921037B2
(en)
|
2008-12-16 |
2014-12-30 |
Bo Han |
PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair
|
|
WO2010118309A2
(en)
*
|
2009-04-10 |
2010-10-14 |
Board Of Regents, The University Of Texas System |
Inhibitors of stat3 and uses thereof
|
|
AU2010236389A1
(en)
|
2009-04-15 |
2011-11-24 |
Nationwide Children's Hospital, Inc. |
Curcumin analogs as dual JAK2/STAT3 inhibitors and methods of making and using the same
|
|
EP2473531A4
(en)
|
2009-09-03 |
2013-05-01 |
Merck Sharp & Dohme |
Anti-gitr antibodies
|
|
US8722720B2
(en)
|
2009-10-28 |
2014-05-13 |
Newlink Genetics Corporation |
Imidazole derivatives as IDO inhibitors
|
|
JP2013512248A
(ja)
|
2009-11-24 |
2013-04-11 |
ジ・オハイオ・ステート・ユニバーシティ |
転写因子阻害剤および関連する組成物、製剤および方法
|
|
PH12012500881A1
(en)
|
2009-12-10 |
2017-07-26 |
Hoffmann La Roche |
Antibodies binding preferentially human csf1r extracellular domain 4 and their use
|
|
US8445517B2
(en)
|
2009-12-11 |
2013-05-21 |
Dana-Farber Cancer Institute |
Stat modulators
|
|
KR101778320B1
(ko)
|
2009-12-28 |
2017-09-13 |
잇반샤단호우징 화루마바레프로제쿠토 시엥기코우 |
1,3,4-옥사디아졸-2-카르복사미드 화합물
|
|
JP5998060B2
(ja)
|
2010-03-04 |
2016-09-28 |
マクロジェニクス，インコーポレーテッド |
Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
|
|
CA2789076C
(en)
|
2010-03-05 |
2017-11-21 |
F. Hoffmann-La Roche Ag |
Antibodies against human colony stimulating factor-1 receptor and uses thereof
|
|
CN102918061B
(zh)
|
2010-03-05 |
2016-06-08 |
霍夫曼-拉罗奇有限公司 |
针对人csf-1r的抗体及其用途
|
|
MX378336B
(es)
|
2010-05-04 |
2025-03-10 |
Five Prime Therapeutics Inc |
Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
|
|
EP2585464A2
(en)
|
2010-06-22 |
2013-05-01 |
University Of Central Florida Research Foundation, Inc. |
Substituted 2-(9h-purin-9-yl) acetic acid analogues as inhibitors of stat3
|
|
SG186389A1
(en)
|
2010-06-30 |
2013-01-30 |
Univ Brandeis |
Small-molecule-targeted protein degradation
|
|
CN103608010A
(zh)
|
2010-08-02 |
2014-02-26 |
中央佛罗里达大学研究基金公司 |
作为stat蛋白的抑制剂的取代的2-羟基-4-(2-(苯基磺酰氨基)乙酰氨基)苯甲酸类似物
|
|
PT2614082T
(pt)
|
2010-09-09 |
2018-12-03 |
Pfizer |
Moléculas de ligação a 4-1bb
|
|
AU2011338615B2
(en)
|
2010-12-07 |
2017-07-27 |
Yale University |
Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
WO2012078982A2
(en)
|
2010-12-09 |
2012-06-14 |
The Ohio State University |
Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells
|
|
WO2012097351A1
(en)
|
2011-01-14 |
2012-07-19 |
The Ohio State University Research Foundation |
Materials and methods to inhibit multiple myeloma cancer cells
|
|
WO2012142615A2
(en)
|
2011-04-14 |
2012-10-18 |
Board Of Regents, The University Of Texas System |
Auranofin and auranofin analogs useful to treat proliferative disease and disorders
|
|
NO2694640T3
(https=)
|
2011-04-15 |
2018-03-17 |
|
|
|
KR101970025B1
(ko)
|
2011-04-20 |
2019-04-17 |
메디뮨 엘엘씨 |
Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
|
|
HRP20201595T1
(hr)
|
2011-11-28 |
2020-12-11 |
Merck Patent Gmbh |
Anti-pd-l1 protutijela i njihova uporaba
|
|
BR112014012624A2
(pt)
|
2011-12-15 |
2018-10-09 |
F Hoffmann-La Roche Ag |
anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
|
|
WO2013106646A2
(en)
|
2012-01-12 |
2013-07-18 |
Yale University |
Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
|
|
CA2861066C
(en)
|
2012-01-12 |
2024-01-02 |
Yale University |
Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
|
|
RU2014136332A
(ru)
|
2012-02-06 |
2016-03-27 |
Дженентек, Инк. |
Композиции и способы применения ингибиторов csf1r
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
EP2847220A1
(en)
|
2012-05-11 |
2015-03-18 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
CA2874057A1
(en)
|
2012-05-25 |
2013-11-28 |
The Governing Council Of The University Of Toronto |
New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
|
|
EP3406598B1
(en)
|
2012-06-14 |
2020-01-29 |
Mayo Foundation for Medical Education and Research |
Pyrazole derivatives as inhibitors of stat3
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
BR112015002285B1
(pt)
|
2012-08-09 |
2022-05-10 |
Celgene Corporation |
Uso do composto 3-(4-((4-(morfolinometil)benzil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona para tratar ou gerenciar câncer
|
|
WO2014028909A1
(en)
|
2012-08-16 |
2014-02-20 |
Ohio State Innovation Foundation |
Stat3 inhibitors and their anticancer use
|
|
CN107759690A
(zh)
|
2012-08-31 |
2018-03-06 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
US9422331B2
(en)
|
2012-09-19 |
2016-08-23 |
Hoffmann-La Roche Inc. |
2-oxo-2,3,4,5-tetrahydro-1 H-benzo[B]diazepines and their use in the treatment of cancer
|
|
US9758522B2
(en)
|
2012-10-19 |
2017-09-12 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
|
US9822135B2
(en)
|
2012-10-30 |
2017-11-21 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
STAT3 dimerization inhibitors
|
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
|
WO2014142237A1
(ja)
|
2013-03-15 |
2014-09-18 |
日本ゼオン株式会社 |
中空重合体粒子の水性分散液およびその製造方法
|
|
EP2975936A4
(en)
|
2013-03-22 |
2017-03-15 |
University of Hawaii |
Novel stat3 inhibitors
|
|
US9765099B2
(en)
|
2013-05-08 |
2017-09-19 |
Board Of Regents, The University Of Texas System |
STAT6 inhibitors
|
|
WO2014205416A1
(en)
|
2013-06-20 |
2014-12-24 |
University Of Hawaii |
Novel sesquiterpenoid stat3 inhibitors
|
|
JP6680683B2
(ja)
|
2013-11-18 |
2020-04-15 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
テトラヒドロ−ベンゾジアゼピノン類
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US20160058872A1
(en)
|
2014-04-14 |
2016-03-03 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
AU2015247817C1
(en)
|
2014-04-14 |
2022-02-10 |
Arvinas Operations, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
WO2015200795A1
(en)
|
2014-06-27 |
2015-12-30 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
|
|
US20160022642A1
(en)
|
2014-07-25 |
2016-01-28 |
Yale University |
Compounds Useful for Promoting Protein Degradation and Methods Using Same
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
KR101697062B1
(ko)
|
2014-08-26 |
2017-01-18 |
한국생명공학연구원 |
물에 대한 용해도가 개선된 신규 제라닐 프라보노이드 유도체, 이의 제조 방법 및 이를 유효성분으로 포함하는 암 예방 및 치료용 약학적 조성물
|
|
KR20160066490A
(ko)
|
2014-12-02 |
2016-06-10 |
주식회사 씨앤드씨신약연구소 |
헤테로사이클 유도체 및 그의 용도
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
JP6815318B2
(ja)
|
2014-12-23 |
2021-01-20 |
ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド |
二官能性分子によって標的化タンパク質分解を誘導する方法
|
|
US10618914B2
(en)
|
2015-01-15 |
2020-04-14 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-B][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
CN112353938A
(zh)
|
2015-02-05 |
2021-02-12 |
特尔诺沃有限公司 |
用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
|
|
US10730870B2
(en)
|
2015-03-18 |
2020-08-04 |
Arvinas Operations, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
HUE054149T2
(hu)
|
2015-06-04 |
2021-08-30 |
Arvinas Operations Inc |
Proteolízis imid-alapú modulátorai és ezekkel kapcsolatos felhasználási eljárások
|
|
SE539204C2
(en)
|
2015-06-05 |
2017-05-09 |
Glactone Pharma Dev Ab |
Ether analogues of galiellalactone
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
CN105085620B
(zh)
|
2015-06-25 |
2018-05-08 |
中山大学附属第一医院 |
一种靶向泛素化降解Smad3的化合物
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
WO2017011371A1
(en)
*
|
2015-07-10 |
2017-01-19 |
Arvinas, Inc |
Mdm2-based modulators of proteolysis and associated methods of use
|
|
CA2988436A1
(en)
|
2015-07-13 |
2017-01-19 |
Arvinas, Inc. |
Alanine-based modulators of proteolysis and associated methods of use
|
|
US10669234B2
(en)
|
2015-07-14 |
2020-06-02 |
Mission Therapeutics Limited |
Cyanopyrrolidines as dub inhibitors for the treatment of cancer
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
KR102650026B1
(ko)
|
2015-09-18 |
2024-03-22 |
메르크 파텐트 게엠베하 |
Irak 억제제로서의 헤테로아릴 화합물 및 이의 용도
|
|
AU2016349781A1
(en)
|
2015-11-02 |
2018-05-10 |
Yale University |
Proteolysis targeting chimera compounds and methods of preparing and using same
|
|
US20200216454A1
(en)
|
2015-12-30 |
2020-07-09 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molecules for her3 degradation and methods of use
|
|
US20190016703A1
(en)
|
2015-12-30 |
2019-01-17 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional compounds for her3 degradation and methods of use
|
|
US11395820B2
(en)
|
2016-03-16 |
2022-07-26 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Small molecules against cereblon to enhance effector t cell function
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
WO2017176958A1
(en)
|
2016-04-06 |
2017-10-12 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
|
AU2017246452C1
(en)
|
2016-04-06 |
2021-06-03 |
The Regents Of The University Of Michigan |
MDM2 protein degraders
|
|
EP3454862B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
EP4491236A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
WO2017197056A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Bromodomain targeting degronimers for target protein degradation
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
WO2017201069A1
(en)
|
2016-05-18 |
2017-11-23 |
Biotheryx, Inc. |
Oxoindoline derivatives as protein function modulators
|
|
EP3458101B1
(en)
|
2016-05-20 |
2020-12-30 |
H. Hoffnabb-La Roche Ag |
Protac antibody conjugates and methods of use
|
|
GB201610147D0
(en)
|
2016-06-10 |
2016-07-27 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
IL290809B2
(en)
|
2016-11-01 |
2024-01-01 |
Arvinas Operations Inc |
Tau-protein targeting protacs and associated methods of use
|
|
CA3042731A1
(en)
|
2016-11-22 |
2018-05-31 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
|
|
SE1651594A1
(sv)
|
2016-12-05 |
2018-05-29 |
Glactone Pharma Dev Ab |
Sulfonamide analogues of galiellalactone
|
|
EP3570836A4
(en)
|
2017-01-23 |
2020-08-19 |
The University of Hawaii |
2-ARYLSULFONAMIDO-N-ARYLACETAMIDE STAT3 INHIBITORS
|
|
BR112019015484A2
(pt)
|
2017-01-31 |
2020-04-28 |
Arvinas Operations Inc |
ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
|
|
EP4717317A2
(en)
|
2017-06-20 |
2026-04-01 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
CN118108706A
(zh)
|
2017-09-04 |
2024-05-31 |
C4医药公司 |
戊二酰亚胺
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
EP3700901A1
(en)
|
2017-10-24 |
2020-09-02 |
Genentech, Inc. |
(4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
|
|
WO2019084030A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
|
|
EP3710002A4
(en)
|
2017-11-16 |
2021-07-07 |
C4 Therapeutics, Inc. |
DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
US11802132B2
(en)
|
2018-02-23 |
2023-10-31 |
Dana-Farber Cancer Institute, Inc. |
Small molecules for inducing selective protein degradation and uses thereof
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
US20220356185A1
(en)
|
2018-07-06 |
2022-11-10 |
Kymera Therapeutics, Inc. |
Mertk degraders and uses thereof
|
|
JP7623943B2
(ja)
|
2018-11-30 |
2025-01-29 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
CN114269763A
(zh)
|
2019-03-26 |
2022-04-01 |
美国密歇根州立大学试剂中心 |
Stat3的小分子降解剂
|
|
WO2020205467A1
(en)
*
|
2019-03-29 |
2020-10-08 |
The Regents Of The University Of Michigan |
Stat3 protein degraders
|
|
TWI875749B
(zh)
|
2019-04-05 |
2025-03-11 |
美商凱麥拉醫療公司 |
Stat降解劑及其用途
|
|
WO2020264490A1
(en)
|
2019-06-28 |
2020-12-30 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
BR112021026517A2
(pt)
|
2019-06-28 |
2022-05-10 |
Kymera Therapeutics Inc |
Degradadores de irak e usos dos mesmos
|
|
US20220281831A1
(en)
|
2019-07-15 |
2022-09-08 |
Kymera Therapeutics, Inc. |
Fused-glutarimide crbn ligands and uses thereof
|
|
WO2021011634A1
(en)
|
2019-07-15 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021011871A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Mertk degraders and uses thereof
|
|
US12551564B2
(en)
|
2019-12-10 |
2026-02-17 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
WO2021127190A1
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
US20230219945A1
(en)
|
2019-12-17 |
2023-07-13 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
US20230122219A1
(en)
|
2020-02-03 |
2023-04-20 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
IL296334A
(en)
|
2020-03-17 |
2022-11-01 |
Kymera Therapeutics Inc |
Stat degraders and uses thereof
|
|
US12522623B2
(en)
|
2020-03-26 |
2026-01-13 |
Regents Of The University Of Michigan |
Small molecule STAT protein degraders
|
|
JP2023545730A
(ja)
|
2020-10-07 |
2023-10-31 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｓｔａｔ分解剤およびそれらの使用
|
|
JP2024545125A
(ja)
|
2021-12-11 |
2024-12-05 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｓｔａｔ３分解剤およびその使用
|